Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure BioSciences CEO says company poised for 'solid year' in 2018

CEO sees assets such as BaroFold, Ultra Shear taking firm 'further down the road to profitability'
Lab tech typing on laptop
The life-science group makes laboratory devices

Pressure BioSciences Inc. (OTCQB:PBIO) Chief Executive Officer Richard T. Schumacher said he expects 2018 to be “another solid year” for the Massachusetts-based company, helped in part by the acquisition of BaroFold intellectual property.

“The results we achieved in 2017 were especially rewarding in that they were achieved with only one dedicated salesperson,” Schumacher said recently on Uptick Newswire’s “Stock Day” podcast. “The enhancements we are implementing in our products, our sales and marketing capabilities, and our corporate infrastructure will allow us to better design, create, sell, support and distribute our product line in 2018.”

READ: Pressure BioSciences reports 20% bump in 4Q sales, expects continued growth in its main business

The life-science group that makes laboratory devices said last week that fourth-quarter sales gained 20% as its product and services business continues to grow. Pressure BioSciences's sales of instruments rose 55% to US$317,498 in the quarter and 21% to US$1.46mln for the full year. Revenue for consumables gained 20% to US$60,108 in the quarter, while it climbed 30% to US$260,331 for the year.

The CEO also cited new patents in Pressure BioSciences’s Ultra Shear Technology platform and the release of its GMP-compliant software as areas that will contribute to results this year.

“We believe these new assets will help expand our customer base, take us further down the path to profitability and help increase shareholder value,” Schumacher said.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use